GlaxoSmithKline

Pharmaceuticals
GSK
$ 31 1.5
Share price
$ 60 bn
Market Cap
$ 83 bn
Enterprise Value

Carbon footprint

10 Ton
GHG emissions per $ 1 mln investment
0.26x the weighted average for S&P 500
FY2021
How is this calculated?
-15%
YOY change in GHG emissions
Weaker than the +5% weighted average for S&P 500
FY2021 vs. previous year

Primary Climate Goal

-11%
Proj. YOY change in GHG emissions (Scope 1 + 2)
Stronger than the -6.6% weighted average for S&P 500
FY2022
How is this calculated?

GlaxoSmithKline aims to achieve net zero for Scope 1 + 2 by 2030


This target has not been verified as science based according to SBTi
GlaxoSmithKline's actual and proj. GHG emissions (Scope 1 + 2) (Kt of CO2e)

Secondary Climate Goal

-10%
Proj. YOY change in GHG emissions (all Scopes)
Stronger than the -7.1% weighted average for S&P 500
FY2021
How is this calculated?

GlaxoSmithKline aims to achieve net zero for all Scopes by 2030


This target has not been verified as science based according to SBTi
GlaxoSmithKline's actual and proj. GHG emissions (all Scopes) (Kt of CO2e)

GHG emissions and Carbon intensity

GlaxoSmithKline's GHG emissions (market-based) (Kt of CO2e)
GlaxoSmithKline's Carbon intensity (Tons per 1 USDm)

GlaxoSmithKline's carbon footprint

GlaxoSmithKline reported Total CO2e Emissions - Market-Based Scope 1 + Scope 2 for the twelve months ending 31 December 2021 at 840 Kt (-151 /-15.2% y-o-y). Also positively, carbon intensity was down at 18 t (-4.5 /-20.1% y-o-y).

GlaxoSmithKline's Scope 3 emissions was down at 13,456 Kt (-1,164 /-8% y-o-y). The decline accelerated compared to the CAGR of -5.3% since 4Q'15.

The company is committed to achieving net zero for Scope 1 + 2 by 2030, which translates into the estimated reduction of -93 Kt per annum over the period of FY2022 - FY2030. This target, however, has not been recognised as science-based (and as aligned with Paris Agreement) by the SBTi.

Also, the company commits to achieving net zero for all Scopes by 2030, which translates into the estimated reduction of -1,445 Kt per annum over the period of FY2021 - FY2030. This target, however, has not been recognised as science-based (and as aligned with Paris Agreement) by the SBTi.

Also, the company commits to achieving net zero for Scope 3 by 2030, which translates into the estimated reduction of -1,346 Kt per annum over the period of FY2021 - FY2030. This target, however, has not been recognised as science-based (and as aligned with Paris Agreement) by the SBTi.

GlaxoSmithKline also has a science-based goal that, however, does not appear to explicitly target a company-wide reduction in emissions in absolute terms. “GlaxoSmithKline commits to reduce absolute scope 1 and 2 GHG emissions 34% by 2025 from a 2017 base year. GSK also commits to reduce absolute scope 3 GHG emissions 16% by 2030 from a 2017 base year.”

Company environmental metrics

Show more...